ReviewFrontiers in psychiatry2026
Neuropathic pain in diabetic patients: a review of pharmacological treatment selection according to psychopathological and somatic factors.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes and its complications are becoming an increasingly significant challenge for modern medicine. Diabetes carries a high risk of various complications, including neuropathic pain and certain mental disorders. It is important to note that these two types of complications often interact with each other. Neuropathic pain occurs in up to approximately 50% of patients and is much more common in those with poorly controlled diabetes. A characteristic feature of this type of pain is that it is usually chronic and resistant to conventional analgesics. This limits the available treatment options and necessitates the use of other medications, including certain psychotropic drugs. Among the most common psychiatric disorders are anxiety disorders, which affect about 18% of patients; depressive disorders, present in over 17% of individuals with type 2 diabetes; and sleep disorders, occurring in about 39% of patients. These complications require appropriate and comprehensive management, which cannot always be provided solely by specialists from specific medical fields. Furthermore, it is beneficial to use therapeutic strategies that combine efficacy in alleviating neuropathic pain with an effect on co-occurring psychiatric symptoms. Our search covered the last ten years, was conducted in the databases PubMed and ScienceDirect. The manuscript includes English-language publications, primarily review articles and recommendations that are as up-to-date as possible. The aim of this review is to present the principles of selecting pharmacological treatment for neuropathic pain in patients with diabetes, taking into account coexisting symptoms of depression, anxiety, and sleep disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.